ArticleFrontiers in molecular biosciences2025
Identification and validation of potential shared diagnostic markers for sepsis-induced ARDS and cardiomyopathy via WGCNA and machine learning.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Insights into Clinical, Molecular, and Therapeutic Approaches to Acute Respiratory Distress Syndrome.Medical sciences (Basel, Switzerland) · 2026Review
- Integrative perspectives on electroacupuncture modulation of vagal-cholinergic and neuro-immune-metabolic regulation in long COVID.Frontiers in integrative neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis frequently results in complications such as acute respiratory distress syndrome (ARDS) and cardiomyopathy. This study aims to identify common diagnostic markers and elucidate the underlying mechanisms of these sepsis-induced complications. Methods: We obtained datasets related to ARDS and sepsis-induced cardiomyopathy (SIC) from the GEO database and applied weighted gene co-expression network analysis (WGCNA) to identify differentially expressed genes (DEGs), which were integrated with key module genes. Feature genes were selected using support vector machine-recursive feature elimination (SVM-RFE) and random forest (RF) algorithms. An artificial neural network (ANN) model was constructed and its diagnostic performance was evaluated using receiver operating characteristic (ROC) curves. Machine learning algorithms effectively identified key hub genes associated with sepsis-induced ARDS and cardiomyopathy, with their robustness validated through ROC analysis. A cellular model of sepsis-induced lung injury was employed to examine hub gene expression. Additionally, we investigated inflammation and immune responses by characterizing immune landscapes using CIBERSORT and performing correlation analyses among feature genes, immune infiltration, and clinical characteristics. Finally, potential small-molecule compounds were identified from the PubChem database. Results: Five key genes-LCN2, AIF1L, STAT3, SOCS3 and SDHD-were identified. SOCS3 showed strong diagnostic potential with gene set enrichment analysis (GSEA) highlighting its role in biological processes and immune responses. SOCS3 expression correlated strongly with immune cells. Dexamethasone, resveratrol and curcumin were identified as potential SOCS3-targeting drugs. Conclusion: Five genes were identified as diagnostic biomarkers for sepsis-induced ARDS and cardiomyopathy, with SOCS3 serving as a key hub gene and potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.